AKAlena A. Kozlova

Alena A. Kozlova

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Alena A. Kozlova has a total of 28 co-authors. Here are the top co-authors by number of shared publications:

  • Elena Rubets

    Division of Angiology, Department of Internal Medicine III, University Center for Vascular Medicine, Technische Universität Dresden, Dresden, Germany

    2 shared publications
  • Nadine Bernhardt

    Department of Psychiatry and Psychotherapy, Faculty of Medicine Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany

    2 shared publications
  • Natalia Jarzebska

    Division of Angiology, Department of Internal Medicine III, University Center for Vascular Medicine, Technische Universität Dresden, Dresden, Germany

    2 shared publications
  • Raul R. Gainetdinov

    Institute of Translational Biomedicine, St. Petersburg State University, Universitetskaya nab. 7/9, 199034 St. Petersburg, Russia

    2 shared publications
  • Roman N. Rodionov

    Department of Internal Medicine III, University Hospital Carl Gustav Carus, Technische Universität Dresden, 01307 Dresden, Germany

    2 shared publications
  • Vinitha N. Ragavan

    Division of Angiology, Department of Internal Medicine III, University Center for Vascular Medicine, Technische Universität Dresden, Dresden, Germany

    2 shared publications

Latest Publications

  • Open Access

    Knock-out of the critical nitric oxide synthase regulator DDAH1 in mice impacts amphetamine sensitivity and dopamine metabolism

    by Alena A. Kozlova, Elena Rubets, Magdalini R. Vareltzoglou, Natalia Jarzebska, Vinitha N. Ragavan, Yingjie Chen, Jens Martens-Lobenhoffer, Stefanie M. Bode-Böger, Raul R. Gainetdinov, Roman N. Rodionov, et al.

    The enzyme dimethylarginine dimethylaminohydrolase 1 (DDAH1) plays a pivotal role in the regulation of nitric oxide levels by degrading the main endogenous nitric oxide synthase inhibitor asymmetric dimethylarginine (ADMA). Growing evidence highlight the potential implication of DDAH/ADMA axis in the etiopathogenesis of several neuropsychiatric and neurological disorders, yet the underlying molecular mechanisms remain elusive. In this study, we sought to investigate the role of DDAH1 in behavioral endophenotypes with neuropsychiatric relevance. To achieve this, a global DDAH1 knock-out (DDAH1-ko) mouse strain was employed. Behavioral testing and brain region-specific neurotransmitter profiling have been conducted to assess the effect of both genotype and sex. DDAH1-ko mice exhibited increased exploratory behavior toward novel objects, altered amphetamine response kinetics and decreased dopamine metabolite 3,4-dihydroxyphenylacetic acid (DOPAC) level in the piriform cortex and striatum. Females of both genotypes showed the most robust amphetamine response. These results support the potential implication of the DDAH/ADMA pathway in central nervous system processes shaping the behavioral outcome. Yet, further experiments are required to complement the picture and define the specific brain-regions and mechanisms involved.


  • CELLULAR CONTEXT-SPECIFIC GENE REGULATION OF NEUROPSYCHIATRIC DISORDERS IN SINGLE HUMAN NEURONS

    by Siwei Zhang, Hanwen Zhang, Lifang Liang, Lexi Li, Brendan Jamison, Whitney Wood, Alena Kozlova, Alan Sanders, Zhiping Pang, Xin He, et al.

  • Open Access

    Divergent Dimethylarginine Dimethylaminohydrolase Isoenzyme Expression in the Central Nervous System

    by Alena A. Kozlova, Vinitha N. Ragavan, Natalia Jarzebska, Iana V. Lukianova, Anastasia E. Bikmurzina, Elena Rubets, Toshiko Suzuki-Yamamoto, Masumi Kimoto, Arduino A. Mangoni, Raul R. Gainetdinov, et al.

    The endogenous methylated derivative of ʟ-arginine, Nω,Nω′-dimethyl-ʟ-arginine (asymmetric dimethylarginine, ADMA), an independent risk factor in many diseases, inhibits the activity of nitric oxide synthases and, consequently, modulates the availability of nitric oxide. While most studies on the biological role of ADMA have focused on endothelial and inducible nitric oxide synthases modulation and its contribution to cardiovascular, metabolic, and renal diseases, a role in regulating neuronal nitric oxide synthases and pathologies of the central nervous system is less understood. The two isoforms of dimethylarginine dimethylaminohydrolase (DDAH), DDAH1 and DDAH2, are thought to be the main enzymes responsible for ADMA catabolism. A current impediment is limited knowledge on specific tissue and cellular distribution of DDAH enzymes within the brain. In this study, we provide a detailed characterization of the regional and cellular distribution of DDAH1 and DDAH2 proteins in the adult murine and human brain. Immunohistochemical analysis showed a wide distribution of DDAH1, mapping to multiple cell types, while DDAH2 was detected in a limited number of brain regions and exclusively in neurons. Our results provide key information for the investigation of the pathophysiological roles of the ADMA/DDAH system in neuropsychiatric diseases and pave the way for the development of novel selective therapeutic approaches.